SecBot SecBot
Biotech Drug Report Generated Nov 17, 2026

Mytesi

JAGX·Jaguar Health, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approved December 2012).
Why 4/10
Mytesi is an already-approved, marketed drug with no pending regulatory decision for its current HIV-associated diarrhea indication. The next hard catalyst for JAGX is the December 21, 2026 PDUFA date for Canalevia (a different crofelemer drug for dogs), not Mytesi. Mytesi's commercial risk has been transferred to Future Pak, and its prescription volumes are declining. ImpactScore 4 reflects an approved drug with no upcoming binary catalyst.
Actionable Insight NEUTRAL

Mytesi itself has no upcoming binary catalyst; it is a mature, declining product whose commercial risk has been transferred to Future Pak. The next major JAGX catalyst is the December 21, 2026 PDUFA date for Canalevia (crofelemer for chemotherapy-induced diarrhea in dogs), which is a separate drug. For Mytesi specifically, watch for any Future Pak-driven commercial initiatives or potential label expansion, but none are currently scheduled.

Price Chart

Loading chart...

Executive Summary

Mytesi (crofelemer) is an FDA-approved botanical prescription drug for noninfectious diarrhea in HIV/AIDS patients on antiretroviral therapy, originally approved in December 2012. It is owned by Jaguar Health (JAGX) via its Napo Pharmaceuticals subsidiary. In January 2026, Jaguar out-licensed exclusive US marketing rights to Future Pak/Woodward Specialty for $16M upfront, shifting commercial responsibility away from Jaguar. Mytesi prescription volumes have been declining (down ~12% YoY in Q4 2025), and Jaguar has pivoted its focus to rare-disease development programs using crofelemer in a novel liquid formulation for microvillus inclusion disease (MVID) and short bowel syndrome. Mytesi is a mature, approved product with no pending regulatory catalyst for its current indication.

How It Works

Crofelemer is a botanical (plant-derived) drug extracted from the sap of the Croton lechleri tree. It works locally in the gut by blocking two key chloride channels (CFTR and calcium-activated chloride channels) on the surface of intestinal cells. This reduces the excessive secretion of fluid and electrolytes into the bowel, thereby decreasing diarrhea. Because it acts only in the gut and is not absorbed into the bloodstream, it has a low risk of systemic side effects or drug interactions.

Trial Status

Mytesi (crofelemer delayed-release tablets) was FDA approved in December 2012 for symptomatic relief of noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. It is commercially available in the US. Jaguar has out-licensed US marketing to Future Pak as of January 2026. Separately, crofelemer in a novel liquid formulation is in Phase 3/pivotal development for rare pediatric intestinal failure diseases (MVID, short bowel syndrome) with a planned NDA filing in mid-2027.

The Two-Sided Case

▲ Bull Case4
Mytesi is the only FDA-approved prescription drug specifically for noninfectious diarrhea in HIV/AIDS patients, giving it a unique niche with no direct approved competitors.
The January 2026 out-license to Future Pak for $16M upfront (plus milestones) provides non-dilutive capital and eliminates Jaguar's sales and marketing costs (reduced >99% per Q2 2026), improving the company's cost structure.
The FDA granted fee waivers for Mytesi for fiscal 2027 under the Prescription Drug User Fee Act, reducing regulatory cost burden.
The same active ingredient (crofelemer) is being developed for rare pediatric intestinal failure diseases (MVID, SBS) with a planned mid-2027 NDA filing, which could eventually expand the commercial opportunity.
▼ Bear Case5
Mytesi prescription volumes have been declining: down 5.8% sequentially and 12.2% year-over-year in Q4 2025, signaling ongoing weakness in core HIV-related sales.
The HIV-associated diarrhea market is a narrow niche, and the drug faces competition from OTC antidiarrheals and improved HIV antiretroviral regimens that cause fewer GI side effects.
Jaguar has effectively exited direct commercialization of Mytesi via the Future Pak license, meaning future revenue is limited to license fees and royalties rather than direct product sales growth.
The company has a history of dilutive financing (multiple S-3 filings, reverse stock splits in 2026) and a very thin post-split float, creating high volatility risk.
Institutional ownership is minimal; only 5 tracked 13F managers hold JAGX with a combined ~$42K in reported value as of Q3 2026.

Upcoming Catalysts

  • No upcoming binary catalyst specifically for Mytesi. The next JAGX catalyst is the December 21, 2026 PDUFA date for Canalevia (crofelemer for chemotherapy-induced diarrhea in dogs). For the broader crofelemer pipeline, a mid-2027 NDA filing is planned for MVID (microvillus inclusion disease), an ultrarare pediatric intestinal failure condition.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Jaguar Health, Inc. 8-K JAGX ·Originating report

Sources · 7

Hover a chip for the title
1 morningstar.com2 fool.com3 biospace.com4 pulse2.com5 usatoday.com6 msn.com7 msn.com